215 related articles for article (PubMed ID: 22147694)
21. Wild-type p53 oligomerizes more efficiently than p53 hot-spot mutants and overcomes mutant p53 gain-of-function via a "dominant-positive" mechanism.
Walerych D; Pruszko M; Zyla L; Wezyk M; Gaweda-Walerych K; Zylicz A
Oncotarget; 2018 Aug; 9(62):32063-32080. PubMed ID: 30174797
[TBL] [Abstract][Full Text] [Related]
22. Influences of the p53 status on hypoxia-induced gene expression.
Liu J; Shibata T; Qu R; Ogura M; Hiraoka M
J Radiat Res; 2004 Jun; 45(2):333-9. PubMed ID: 15304978
[TBL] [Abstract][Full Text] [Related]
23. Hsp90 is essential for restoring cellular functions of temperature-sensitive p53 mutant protein but not for stabilization and activation of wild-type p53: implications for cancer therapy.
Müller P; Ceskova P; Vojtesek B
J Biol Chem; 2005 Feb; 280(8):6682-91. PubMed ID: 15613472
[TBL] [Abstract][Full Text] [Related]
24. Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators.
Roemer K
Biol Chem; 1999; 380(7-8):879-87. PubMed ID: 10494837
[TBL] [Abstract][Full Text] [Related]
25. HIF-transcribed p53 chaperones HIF-1α.
Madan E; Parker TM; Pelham CJ; Palma AM; Peixoto ML; Nagane M; Chandaria A; Tomás AR; Canas-Marques R; Henriques V; Galzerano A; Cabral-Teixeira J; Selvendiran K; Kuppusamy P; Carvalho C; Beltran A; Moreno E; Pati UK; Gogna R
Nucleic Acids Res; 2019 Nov; 47(19):10212-10234. PubMed ID: 31538203
[TBL] [Abstract][Full Text] [Related]
26. [Advances on mutant p53 research].
Li DH; Zhang LQ; He FC
Yi Chuan; 2008 Jun; 30(6):697-703. PubMed ID: 18550490
[TBL] [Abstract][Full Text] [Related]
27. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
Stiewe T; Haran TE
Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
[TBL] [Abstract][Full Text] [Related]
28. A common gain of function of p53 cancer mutants in inducing genetic instability.
Liu DP; Song H; Xu Y
Oncogene; 2010 Feb; 29(7):949-56. PubMed ID: 19881536
[TBL] [Abstract][Full Text] [Related]
29. Modulation of wild-type p53 activity by mutant p53 R273H depends on the p53 responsive element (p53RE). A comparative study between the p53REs of the MDM2, WAFI/Cip1 and Bax genes in the lung cancer environment. WAFI/Cip1 = WAF1/Cip1.
Zacharatos PV; Gorgoulis VG; Kotsinas A; Manolis EN; Liloglou T; Rassidakis AN; Kanavaros P; Field JD; Halazonetis T; Kittas C
Anticancer Res; 1999; 19(1A):579-87. PubMed ID: 10226602
[TBL] [Abstract][Full Text] [Related]
30. Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine.
Orue A; Chavez V; Strasberg-Rieber M; Rieber M
BMC Cancer; 2016 Nov; 16(1):902. PubMed ID: 27863474
[TBL] [Abstract][Full Text] [Related]
31. Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer.
Silva JL; Cino EA; Soares IN; Ferreira VF; A P de Oliveira G
Acc Chem Res; 2018 Jan; 51(1):181-190. PubMed ID: 29260852
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological rescue of mutant p53 conformation and function.
Foster BA; Coffey HA; Morin MJ; Rastinejad F
Science; 1999 Dec; 286(5449):2507-10. PubMed ID: 10617466
[TBL] [Abstract][Full Text] [Related]
33. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent.
Whitesell L; Sutphin PD; Pulcini EJ; Martinez JD; Cook PH
Mol Cell Biol; 1998 Mar; 18(3):1517-24. PubMed ID: 9488468
[TBL] [Abstract][Full Text] [Related]
34. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
35. Analysis of a mutant p53 protein arising in a medulloblastoma from a mouse transgenic for the JC virus early region.
White MK; Skowronska A; Gordon J; Del Valle L; Deshmane SL; Giordano A; Khalili K
Anticancer Res; 2006; 26(6B):4079-92. PubMed ID: 17201119
[TBL] [Abstract][Full Text] [Related]
36. Hypoxia and reoxygenation: a pressure for mutant p53 cell selection and tumour progression.
Thompson KE; Royds JA
Bull Math Biol; 1999 Jul; 61(4):759-78. PubMed ID: 17883223
[TBL] [Abstract][Full Text] [Related]
37. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
38. CHIP chaperones wild type p53 tumor suppressor protein.
Tripathi V; Ali A; Bhat R; Pati U
J Biol Chem; 2007 Sep; 282(39):28441-28454. PubMed ID: 17666403
[TBL] [Abstract][Full Text] [Related]
39. Molecular alterations and lung tumors in p53 mutant mice exposed to cigarette smoke.
De Flora S; Balansky RM; D'Agostini F; Izzotti A; Camoirano A; Bennicelli C; Zhang Z; Wang Y; Lubet RA; You M
Cancer Res; 2003 Feb; 63(4):793-800. PubMed ID: 12591728
[TBL] [Abstract][Full Text] [Related]
40. Wild-type p53 and a p53 temperature-sensitive mutant suppress human soft tissue sarcoma by enhancing cell cycle control.
Pollock R; Lang A; Ge T; Sun D; Tan M; Yu D
Clin Cancer Res; 1998 Aug; 4(8):1985-94. PubMed ID: 9717829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
